Literature DB >> 26365020

Development of albumin-based nanoparticles for the delivery of abacavir.

Barnabas Wilson1, Latishkumar Paladugu2, S R Brahmani Priyadarshini2, J Josephine Leno Jenita2.   

Abstract

The study was designed to prepare and evaluate albumin nanoparticles containing antiviral drug abacavir sulphate. Various batches of albumin nanoparticles containing abacavir sulphate were prepared by desolvation method. The abacavir loaded particles were characterized for their yield, percentage of drug loading, surface morphology, particle size, surface charge, pattern of in vitro drug release and release mechanism studies. Drug loading ranged from 1.2 to 5.9%w/w. The mean particle size and the surface charge were 418.2nm and -40.8mV respectively. The in vitro drug release varied between 38.73 and 51.36%w/w for 24h. The n value for Korsmeyer-Peppas was 0.425 indicating Fickian type drug release. The preliminary findings indicated that albumin nanoparticles of abacavir can be prepared by desolvation method with good yield, high drug loading and sustained release.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abacavir; Albumin nanoparticles; HIV/AIDS treatment

Mesh:

Substances:

Year:  2015        PMID: 26365020     DOI: 10.1016/j.ijbiomac.2015.09.015

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  3 in total

1.  Development and characterization of a long-acting nanoformulated abacavir prodrug.

Authors:  Dhirender Singh; JoEllyn McMillan; James Hilaire; Nagsen Gautam; Diana Palandri; Yazen Alnouti; Howard E Gendelman; Benson Edagwa
Journal:  Nanomedicine (Lond)       Date:  2016-07-26       Impact factor: 5.307

Review 2.  Nanomedicine to deliver biological macromolecules for treating COVID-19.

Authors:  Barnabas Wilson; Kannoth Mukundan Geetha
Journal:  Vaccine       Date:  2022-05-30       Impact factor: 4.169

Review 3.  Lipid nanoparticles in the development of mRNA vaccines for COVID-19.

Authors:  Barnabas Wilson; Kannoth Mukundan Geetha
Journal:  J Drug Deliv Sci Technol       Date:  2022-06-28       Impact factor: 5.062

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.